WO2011059457A1

WO2011059457A1 - High performance luminescent compounds

Info

Publication number: WO2011059457A1
Application number: PCT/US2009/064621
Authority: WO
Inventors: Bradley Smith; Arunkumar Easwaran
Original assignee: University Of Notre Dame Du Lac; Molecular Targeting Technologies, Inc.
Priority date: 2009-11-16
Filing date: 2009-11-16
Publication date: 2011-05-19

Abstract

Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to novel near-infrared dyes that are photostable and resistant to quenching. The dyes belong to a novel family of squaraine rotaxanes, and they are particularly well-suited for use in biological applications. Also disclosed are methods of synthesizing the dyes and methods of using the dyes.

Description

HIGH PERFORMANCE LUMINESCENT COMPOUNDS

Government Interests

[0001] This invention was made with Government support under Grants GM059078 and EB009266 awarded by the National Institutes of Health. The Government has certain rights in the invention.

Technical Field

[0002] Embodiments herein relate to the field of chemistry, and, more specifically, to novel luminescent compounds, synthesis thereof, and methods of using same.

Background

[0003] Squaraine dyes are organic dyes with very intense

fluorescence spectra, typically in the red and near infrared region, which makes them attractive for biological applications. They are characterized by an aromatic four-membered ring system derived from squaric acid.

[0004] Some squaraine dyes may be conjugated to biomolecules through a free carboxylic acid group. However, these lipophilic squaraine dyes suffer from three problems in physiological solutions: poor solubility, massive aggregation-induced loss of fluorescence signal, and poor stability. Even sulfonated squaraine derivatives that are water-soluble are still unstable in PBS.

[0005] Most squaraines are encumbered by nucleophilic attack of the central four-membered ring, which is highly electron deficient. This encumbrance may be attenuated by trapping the squaraine inside a macrocycle to form a permanently interlocked molecule called a squaraine rotaxane. Formation of a rotaxane around the dye helps to protect it from nucleophiles, which improves the stability of squaraine dyes in physiological solutions like phosphate buffered saline (PBS). However, squaraine rotaxanes still lose fluorescence signal under very strong aggregation conditions such as phosphate buffered saline, which limits their usefulness in biological applications.

Brief Description of the Drawings

[0006] Embodiments will be readily understood by the following detailed description in conjunction with the accompanying drawings.

Embodiments are illustrated by way of example and not by way of limitation in the figures of the accompanying drawings.

[0007] Figure 1 illustrates the synthesis of symmetric and

unsymmetric squaraine dyes, according to various embodiments.

[0008] Figure 2 illustrates absorption spectra of an aggregated squaraine rotaxane 3 in DMSO: PBS (1 :4), and illustrates a strong aggregate band at 573 nm, in accordance with various embodiments.

[0009] Figure 3 illustrates a typical example of absorption (left peak) and emission (right peak) spectra of a non-aggregated squaraine rotaxane 4 in PBS attached with a single sulfonate group, in accordance with various embodiments.

[0010] Figure 4 illustrates a typical example of absorption (left peak) and emission (right peak) spectra of a non-aggregated squaraine rotaxane 5 in PBS attached with two sulfonate groups, in accordance with various embodiments.

[0011] Figure 5 illustrates a typical example of absorption (left peak) and emission (right peak) spectra of a non-aggregated squaraine rotaxane 6 in PBS attached with a zwitterionic group, in accordance with various embodiments.

[0012] Figure 6 illustrates a photobleaching profile of biotinylated fluorophores, in accordance with various embodiments.

[0013] Figure 7 illustrates exemplary squaraine rotaxane dyes, in accordance with various embodiments. Detailed Description of Disclosed Embodiments

[0014] In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which are shown by way of illustration embodiments that may be practiced. It is to be understood that other embodiments may be utilized and structural or logical changes may be made without departing from the scope. Therefore, the following detailed description is not to be taken in a limiting sense, and the scope of embodiments is defined by the appended claims and their equivalents.

[0015] Various operations may be described as multiple discrete operations in turn, in a manner that may be helpful in understanding embodiments; however, the order of description should not be construed to imply that these operations are order dependent.

[0016] For the purposes of the description, a phrase in the form "A B" or in the form "A and/or B" means (A), (B), or (A and B). For the purposes of the description, a phrase in the form "at least one of A, B, and C" means (A), (B), (C), (A and B), (A and C), (B and C), or (A, B and C). For the purposes of the description, a phrase in the form "(A)B" means (B) or (AB) that is, A is an optional element.

[0017] The description may use the terms "embodiment" or

"embodiments," which may each refer to one or more of the same or different embodiments. Furthermore, the terms "comprising," "including," "having," and the like, as used with respect to embodiments, are

synonymous.

[0018] As used herein, the term "halogen" refers to fluoro, bromo, chloro and iodo substituents.

[0019] As used herein, the term "alkyl" refers to a cyclic, branched, or straight chain alkyl group containing only carbon and hydrogen, and unless otherwise mentioned contains one to twelve carbon atoms. This term may be further exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, adamantyl, and cyclopentyl. Alkyl groups may either be unsubstituted or substituted with one or more substituents, for instance, halogen, alkyl, alkoxy, alkylthio, trifluoromethyl, acyloxy, hydroxy, mercapto, carboxy, aryloxy, aryl, arylalkyl, heteroaryl, amino, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1 -yl, or other functionality.

[0020] As used herein, the term "substituted alkyl" refers to an alkyl moiety including 1-4 substituents selected from halogen, het, cycloalkyi, cycloalkenyl, aryl, amino, cyano, nitro, -OQi₀, -SQi₀, -S(O)₂Qio, -S(O)Qi₀, - OS(O)₂Qio, -C(=NQio)Qio, -C(=NOQio)Qio, -S(O)₂-N=S(O)(Qi₀)2, -S(0)₂- N=S(Qio)2, -NQ10Q10, -C(O)Qio, -C(S)Qio, -C(O)OQi₀, -OC(O)Qi_0> - C(O)NQioQio, -C(S)NQioQio, -N(Qi₀)C(S)NQi₀Qio, -C(0)NQioQio, - C(S)NQ₁₀Qio, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =S, -NQ₁₀C(O)Q₁₀, - NQioC(O)NQioQio, -S(O)₂NQi₀Qio, -NQi₀S(O)₂Qi₀, -NQi₀S(O)Qi_0> - NQ10SQ10, and -SNQioQio- Each of the het, cycloalkyi, cycloalkenyl, and aryl being optionally substituted with 1-4 substituents independently selected from halogen and Q15.

[0021] As used herein, the term "cycloalkyi" refers to a cyclic alkyl moiety. Unless otherwise stated, cycloalkyi moieties include between 3 and 8 carbon atoms.

[0022] Each Q₀ is independently selected from H, alkyl, cycloalkyi, het, cycloalkenyl, and aryl. The het, cycloalkyi, cycloalkenyl, and aryl being optionally substituted with 1-3 substitutuents selected from halo and Q13.

[0023] Each Qn is independently selected from H, halogen, alkyl, aryl, cycloalkyi, and het. The alkyl, aryl, cycloalkyi, and het being optionally substituted with 1-3 substituents independently selected from halogen, nitro, cyano, =S, =O, and Qi₄.

[0024] Each Q13 is independently selected from Qn, -OQn, -SQn, - S(O)₂Qii, -S(O)Qii, -OS(O)₂Qii, -C(=NQ )Q , -S(O)₂-N=S(O)(Qn)₂, - S(O)₂-N=S(Qii)₂, -SC(O)Qii, -NQnQn, -C(O)Qn, -C(S)Qn, -C(O)OQn, - OC(O)Qii, -C(O)NQiiQii, -(S)NQnQn, -C(O)C(Qi₆)₂OC(O)Qi₀, -CN, =O, =S, -NQiiC(O)Qii, -NQiiC(S)Qii, -NQnC(O)NQnQn, -NQnC(S)NQnQn, - S(Q)₂NQiiQii, -NQiiS(O)₂Qii, -NQnS(O)Qn, -NQnSQn, -NO₂, and - SNQ Q . [0025] Each Qi₄ is independently selected from H, alkyl, cycloalkyl, phenyl, or naphthyl, each optionally substituted with 1 -4 substituents independently selected from F, CI, Br, I, -OQi_6> -SQi_6> -S(O)₂Qi₆, -S(0)Qi_6> - OS(O)₂Qi6, -NQ16Q16, -C(0)Qi6, -C(S)Qi6, -C(0)OQi_6> -N0_2> -C(0)NQi₆Qi₆, -C(S)NQi₆Qi6, -CN, -NQi₆C(0)Qi6, -NQi₆C(S)Qi_6> -NQi₆C(O)NQi₆Qi6, - NQi₆C(S)NQi₆Qi6, -S(O)₂NQi₆Qi6, and -NQi₆S(O)₂Qi₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S.

[0026] Each Q ₅ is independently selected from H, alkyl, cycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1 -4 substituents independently selected from F, CI, Br, I, -OQi₆, -SQi₆, - S(O)₂Qi 6, -S(O)Qi 6, -OS(O)₂Qi6, -C(=NQ₁₆)Q₁₆, -S(O)₂-N=S(O)(Qi₆)₂, - S(0)₂-N=S(Qi 6)2, -SC(O)Qi6, -NQ₁₆Q₁₆, -C(0)Qi_6> -C(S)Qi_6> -C(0)OQi_6> - OC(O)Qi 6, -C(S)NQi₆Qi6, -C(O)C(Qi₆)₂OC(O)Qi₆, -CN, -NQi₆C(0)Qi_6> - NQ₁₆C(S)Qi6, -NQ₁₆C(O)NQ₁₆Q₁₆, -NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, - NQi₆S(O)₂Qi 6, -NQi₆S(O)Qi6, -NQi₆SQi₆, -NO₂, and -SNQi₆Qi₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S.

[0027] Each Qi₆ is independently selected from H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1 -3 halogens.

[0028] As used herein, the term "sulfone" refers to a chemical compound containing a sulfonyl functional group attached to two carbon atoms. The central sulfur atom is twice double bonded to oxygen and has two further hydrocarbon substituents. The general structural formula is R- S(=O)(=O)-R' where R and R' are the organic groups.

[0029] As used herein, the term "aryl" refers to phenyl and naphthyl.

[0030] As used herein, the term "heteroaryl" refers to a mono- or bicyclic het in which one or more cyclic ring is aromatic.

[0031] As used herein, the term "substituted heteroaryl" refers to a heteroaryl moiety substituted with one or more functional groups selected from halogen, alkyl, hydroxyl, amino, alkoxy, cyano, and nitro. [0032] As used herein, the term "triazole" refers to either one of a pair of isomeric chemical compounds with molecular formula C2H3N3, having a five-member ring of two carbon atoms and three nitrogen atoms.

[0033] As used herein, the term "sulfonate" refers to an anion with the general formula RSO₂O-. Sulfonates are the conjugate bases of sulfonic acids with formula RSO₂OH.

[0034] As used herein, the term "phosphonate" refers to organic compounds containing C-PO(OH)₂ or C-PO(OR)₂ groups (where R=alkyl or aryl).

[0035] As used herein, the term "succinimide" refers to a cyclic imide with the formula C H₅NO₂.

[0036] As used herein, the term "maleimide" refers to, the chemical compound with the formula H₂C₂(CO)₂NH.

[0037] As used herein, the term "polyethylene glycol" refers to a chemical compound composed of one or more ethoxy units (-OCH₂CH₂-) in a repeating linear series. The series may begin or end with a hydroxyl group (-OH groups) or other functionality.

[0038] As used herein, the term "biotin" refers to a water-soluble B- complex vitamin which is composed of an ureido (tetrahydroimidizalone) ring fused with a tetrahydrothiophene ring. A valeric acid substituent is attached to one of the carbon atoms of the tetrahydrothiophene ring.

[0039] As used herein, the term "dimethylammonium" refers to organic compounds that have four carbons, two of them methyl carbons, attached to a nitrogen atom that has a formal positive charge. Depending on the rest of the molecule there may or may not be a counter anion. It is also understood that in some embodiments the methyl groups may be substituted with longer chain alkyl groups.

[0040] As used herein, the term "zwitterionic group" refers to a group that has both a positive charge and a negative charge when the molecule is in an environment that is close to neutral pH. A molecule may have several attached "zwitterionic groups" [0041] Embodiments of the present disclosure provide a new family of squaraine rotaxane dyes that solve all major problems that known squaraine rotaxanes exhibit in physiological solutions, including: poor solubility, aggregation-induced loss of fluorescence signal, poor stability, only moderate brightness, poor biodistribution in animals, or bioconjugates with greatly altered charge patterns. The novel squaraine rotaxane dyes have photophysical properties that are very similar to the commonly used Cy-5 fluorophore, however, the new dyes are substantially more photostable and they resist quenching. This makes them superior substitutes for Cy-5 in many biotechnological and imaging applications. In some embodiments, the dyes may be conjugated to small and large biological molecules to make fluorescent molecular probes for various imaging applications.

[0042] In some embodiments, the squaraine rotaxanes may include one or more sulfonate or phosphonate groups and also may include one or more reactive sites for bioconjugation. In other embodiments, the squaraine rotaxanes may be uncharged or nearly uncharged overall, but may include one or more zwitterionic groups for water solubility and also may include one or more reactive sites for bioconjugation. Embodiments of the present disclosure encompass any racemic, optically-active, polymorphic,

tautomeric, or stereoisomeric form or mixture thereof, of a compound of the disclosure that possesses the useful properties described herein. Other embodiments include bioconjugates of the squaraine rotaxane dyes disclosed herein. Still other embodiments provide methods of synthesizing the squaraine rotaxane compounds described herein.

[0043] In embodiments, squaraine rotaxanes are made in three major steps; (1 ) fabrication of the central squaraine thread component, (2) encapsulation of this thread component inside a macrocycle to make a rotaxane, and (3) covalent modification of the rotaxane. As described herein, sulfonate, phophonate, or zwitterionic groups are added after the second step since their presence diminishes the synthetic yields in the second step. Reactions that directly attach sulfonate groups via electrophilic addition mechanisms do not produce high yields of products. Embodiments disclose herein a much better approach for attaching a sulfonate or a phosphate group or a zwitterionic group to the squaraine rotaxane.

[0044] In some embodiments, attaching a sulfonate, phophonate, or zwitterionic group to the squaraine rotaxane via amide bond formation is undesirable for bioimaging probes because amide bonds may be broken by enzymatic action. Preferred embodiments involve the conjugation method of forming triazole linkages using a copper catalyzed azide/alkyne cycloaddition reaction. In embodiments, triazoles are excellent linkages because they are resistant to protease enzyme cleavage and their formation does not produce by-products.

[0045] In an embodiment, a squaraine rotaxane may have at least one sulfonate/phosphonate group and/or at least one zwitterionic group, and may have the formul

or a pharmaceutically acceptable salt thereof, wherein: R¹, R², and R³ are each independently alkyi, phenyl, polyethylene glycol, alkyl-phosphonate, alkyl-sulfonate, methylene-triazole-alkyl-sulfonate, methylene-triazole-alkyl- phosphonate, methylene-triazole-methylene-dimethylammonium-alkyl- sulfonate, or methylene-dimethylammonium-alkyl-phosphonate; X = alkyi, phenyl, alkyl-carboxylic acid, alkyi ester, alkyi hydroxysuccinimde ester, alkyi maleimide, alkyi isothiocyanate, alkyi azide, alky alkyne, alkyi

haloacetamido, aryl ester, aryl hydroxysuccinimde ester, aryl maleimide, aryl isothiocyanate, aryl azide, aryl alkyne, or aryl haloacetamido; Y¹ and Y² are each independently H, alkoxy-t azole-methylene-sulfonate, alkoxy-triazole- methylene-dimethylammonium-alkyl-sulfonate, alkoxy-triazole-methylene- phosphonate, alkoxy-triazole-methylene-dimethylammonium-alkyl- phosphonate, t azole-methylene-sulfonate, triazole-methylene- phosphonate, triazole-methylene-dimethylammonium-alkyl-sulfonate, triazole-methylene-methylene-dimethylammonium-alkyl-phosphonate, or one of the reactive groups listed as X; Z¹ and Z² are each independently CH or N; and W¹, W², W³, and W⁴ are each independently H or OH.

[0046] In certain embodiments, the squaraine rotaxane may have the formula:

haloacetamido, aryl ester, aryl hydroxysuccinimde ester, aryl maleimide, aryl isothiocyanate, aryl azide, aryl alkyne, or aryl haloacetamido; Y¹ and Y² are each independently H, alkoxy-triazole- methylene-sulfonate, alkoxy-triazole- methylene-dimethylammonium-alkyl-sulfonate, alkoxy-triazole-methylene- phosphonate, alkoxy-triazole-methylene-dimethylammonium-alkyl- phosphonate, triazole-methylene-sulfonate, triazole-methylene- phosphonate, triazole-methylene-dimethylammonium-alkyl-sulfonate, triazole-methylene-methylene-dimethylammonium-alkyl-phosph or one of the reactive groups listed as X; and W¹, W², W³, and W⁴ are each independently H or OH.

[0047] In certain embodiments, the squaraine rotaxane may have the formula:

haloacetamido, aryl ester, aryl hydroxysuccinimde ester, aryl maleimide, aryl isothiocyanate, aryl azide, aryl alkyne, or aryl haloacetamido, Y¹ and Y² are each independently H, alkoxy-triazole-methylene-sulfonate, alkoxy-triazole- methylene-dimethylammonium-alkyl-sulfonate, alkoxy-triazole-methylene- phosphonate, alkoxy-triazole-methylene-dimethylammonium-alkyl- phosphonate, triazole-methylene-sulfonate, triazole-methylene- phosphonate; triazole-methylene-dimethylammonium-alkyl-sulfonate, triazole-methylene-methylene-dim or one of the reactive groups listed as X; and W¹, W², W³, and W⁴ are each independently H or OH.

[0048] In embodiments, the exemplary compounds described above may be synthesized according to the following general procedures. In some embodiments, symmetrical squaraine dyes are prepared in one step by heating two equivalents of the appropriate aniline derivative with squaric acid. In other embodiments, unsymmetrical squaraines are prepared in two steps via a stable semi squaraine intermediate (see, e.g., Figure 1 ).

[0049] In some embodiments, a subsequent template

macrocyclization step yields a squaraine rotaxane dye, as shown in the example below using an aniline-based squaraine.

[0050] It was not known prior to the present disclosure that this procedure may be used to prepare aniline-based squaraine rotaxanes with ortho-hydroxyl groups on the aniline rings, such as the following example.

[0051] The product of this reaction has the following spectral data. ¹H NMR: 0.96 (t, J = 7.4 Hz, 12H), 1 .30 (dd, J = 7.4 Hz, 7.0 Hz, 8H), 1 .52 (br s, 8H), 3.22 (t, J = 6.6 Hz, 8H), 3.93 (d, J = 14.0 Hz, 4H), 5.08 (m, 6H), 5.98 (d, J = 2.0 Hz, 2H), 6.73 (d, J = 9.0 Hz, 4H), 6.93 (d, J = 9.0 Hz, 4H), 7.73 (d, J = 9.2 Hz, 2H), 8.1 (t, J = 8.0 Hz, 2H), 8.50 (d, J = 7.8 Hz, 4H), 9.88 (d, J = 8.8 Hz, 4H),1 1 .2 (s, 2H); Abs: 651 nm; Em: 672 nm.

[0052] Aniline-based squaraine rotaxanes with ortho-hydroxyl groups are a novel set of squaraine rotaxanes that exhibit highly favorable chemical and photophysical performance, due in part to the hydrogen bonding between the ortho-hydroxyl groups and the squaraine oxygens which provides structural rigidity and blocks chemical attack. Another favorable attribute gained by the presence of ortho-hydroxyl groups is reduced fluorescence quenching by water. This may be demonstrated by comparing compound 1 , which has no ortho-hydroxyls attached to the anilines, with compound 2, which has two ortho-hydroxyls attached to one of the anilines. Photophysical measurements in two solvents, tetrahydrofuran (THF) and THF: water (1 :1 ), show that the fluorescence quantum yield of compound 1 decreases by 33% when the solvent is changed from THF to THF: Water (1 :1 ). This is due to the squaraine quenching effect of water. In contrast, the fluorescence quantum yield of compound 2 is not altered when the solvent is changed from THF to THF: water (1 :1 ). This demonstrates that the fluorescence brightness of squaraine rotaxanes with ortho-hydroxyl groups is insensitive to solvent and local environment, a valuable property in quantitative imaging and sensing technologies.

Compound 1 : In THF; Abs 637 nm; Em 655 nm, QY

(1 :1 ); Abs 644 nm; Em 664 nm, QY = 0.39.

Compound 2: In THF: Abs 640 nm; Em 666 nm, QY

(1 :1 ); Abs 651 nm; Em 677 nm, QY = 0.33. [0053] With anthracene containing macrocycles, a new class of squaraine rotaxane dyes may be formed by a slippage process that involves mixing the squaraine and the macrocycle components and using heat, or microwave radiation to induce the squaraine dye to slip inside the

macrocycle to form a squaraine rotaxane intermediate that may be further modified. One embodiment of this synthesis is as follows.

[0054] The product of this reaction has the following spectral data.

NMR (600 MHz, CDCI₃) 0.89 (m, 6H), 1 .07 (t, J = 7.8 Hz, 3H), 1 .20 (m, 4H), 1 .46 (m, 4H), 1 .71 (m, 2H), 3.42 (m, 8H), 6.53 (d, J = 9.0 Hz, 2H), 6.61 (d, J = 9.0 Hz, 2H), 6.72 (d, J = 9.0 Hz, 1 H), 6.83 (d, J = 8.4 Hz, 1 H), 7.35 (m, 8H), 6.94 (d, J = 8.4 Hz, 1 H), 7.76 (d, J = 9.0 Hz, 4H), 7.82 (d, J = 9.0 Hz, 4H), 8.67 (d, J = 7.8 Hz, 4H), 8.22 (dd, J = 7.8, 4.2 Hz, 2H), 9.76 (t, J = 4.8 Hz, 4H), 1 1 .25 (s, 1 H), 5.37 (d, J = 10 Hz, 8H); Abs: 653 nm; Em: 703 nm.

[0055] Exemplary squaraine rotaxanes with one or more sulfonate or zwitterionic groups attached and one or more reactive sites for

bioconjugation were generated and tested. Efficient and effective methods for attaching sulfonate groups or zwitterionic groups to squaraine rotaxanes were not known prior to the present disclosure. In embodiments, the squaraine rotaxane may be modified and groups may be introduced that provide water solubility and reactivity using the conjugation method of forming triazole linkages using a copper catalyzed azide alkyne cycloaddition reaction, as shown in the following exemplary reaction.

Where A¹, A², A³, A⁴, and A⁵ are each independently H or azido (N₃); T¹ , T², T³, T⁴, and T⁵ are each independently H or 1 ,3-triazole rings; and W¹ , W², W³, and W⁴ are each independently H or OH.

0056] One embodiment of this synthesis is as follows.

[0057] It was not known prior to the present disclosure that particular modifications prevent aggregation of the squaraine rotaxanes in

physiological fluids such as phosphate buffered saline (PBS). Figure 2 shows an exemplary absorption spectrum of unmodified, lipophilic squaraine rotaxane 3 in a DMSO/PBS solvent mixture that promotes aggregation. Aggregates that exhibit the absorption band at 573 nm are not fluorescent.

[0058] Figure 3 illustrates an example of absorption (left peak) and emission (right peak) spectra in PBS of a squaraine rotaxane 4 attached with a single sulfonate group. There is no evidence of non-fluorescent aggregates. Similarly, Figure 4 shows an example of absorption (left peak) and emission (right peak) spectra in PBS of a squaraine rotaxane 5 attached with two sulfonate groups. In further embodiments, squaraine rotaxanes with one or more zwitterionic groups may not form aggregates in PBS. For instance, Figure 5 shows an example of absorption (left peak) and emission (right peak) spectra of a squaraine rotaxane 6 in PBS attached with a zwitterionic group.

[0059] In some embodiments, the squaraine rotaxanes are water soluble but overall uncharged because they have one or more attached polyethylene glycol or zwitterionic groups for water solubility and one or more reactive sites for bioconjugation. The attachment of a dye with many anionic or cationic groups to a biological molecule sometimes changes the charge pattern of the biological molecule to such an extent that its chemical, biochemical or supramolecular properties are altered adversely. In another embodiment, the attachment of a dye having many anionic groups or many cationic groups to a biological molecule produces a bioconjugate that when introduced into an animal is not likely to be cleared primarily from the bloodstream by the kidney, which complicates imaging performance. These problems are solved, in embodiments, by creating squaraine rotaxanes with one or more polyethyleneglycol or zwitterionic groups for water solubility and one or more reactive sites for bioconjugation. In embodiments, the overall net charge of these compounds is zero or close to zero. In embodiments, these compounds have excellent water solubility and excellent stability, do not form non-fluorescent aggregates in PBS, and have a greater tendency to clear from the bloodstream of animals through the kidney.

[0060] Surprisingly, in embodiments, squaraine rotaxanes with one or more attached sulfonates or attached zwitterionic groups are very

photostable, even when they are associated with proteins that normally quench other dyes. The following exemplary probe molecule biotin- squaraine rotaxane (SQR-biotin) was synthesized:

SQR-biotin

The probe SQR-biotin is a squaraine rotaxane with an attached sulfonate that gives excellent water solubility, and an attached biotin group that has strong affinity for the protein avidin or related variants such as streptavidin. The complex of this probe associated with streptavidin is very photostable compared to complexes made with other dyes.

[0061] In one specific, non-limiting example, the photobleaching of commercially available biotin-4-carboxyfluorescein (CF-biotin), and biotin- squaraine rotaxane (SQR-biotin) was examined by measuring the half-life of each of the probes. The dyes were incubated in excess with 1 .3 μιτι magnetic particles coated in avidin. Following the incubation, the particles were washed of any unbound fluorophore, and the samples were then imaged on an epifluorescent microscope. The samples remained under constant excitation and images were captured every 30 seconds. Using ImageJ software, a region of interest (ROI) was drawn around the imaged magnetic particles and the mean pixel intensity was measured for each image. These data were then plotted versus time, and the half-life was calculated. Figure 6 shows the photobleaching profile of the two biotinylated fluorophores. The biotin-4-carboxyfluorescein probe showed dramatic photobleaching, but the biotin-squaraine rotaxane probe retained

fluorescence intensity throughout the duration of the test.

[0062] Figure 7 illustrates a number of specific, non-limiting examples of squaraine rotaxanes. 1. Synthesis of squaraine rotaxanes with the following general structure (or a pharmaceutically acceptable salt thereof):

[0063] According to embodiments, X = OH, alkoxy, aryloxy, NH-alkyl, NH-aryl, N-succinimide, NH-alkyl-maleinnide, NH-polyethylene glycol-biotin, polyethylene glycol, methylene-sulfonate, methylene-dimethylammonium- alkyl-sulfonate, methylene-phosphonate, or methylene-dimethylammonium- alkyl-phosphonate.

[0064] In one specific, non-limiting example, the synthesis of a typical example (below) from this series is as follows:

(a) Synthesis of semi squaraine

[0065] An azide derivative of aniline (1 mmol) is mixed with squaryl chloride (1 .1 mmol) in dry benzene. The mixture is refluxed for 16 hours. Later, the benzene is evaporated to dryness and the crude product is treated with 50% acetic acid (30 mL) and 4N HCI (4 mL) and refluxed for 6 hours. The cooled reaction mixture is transferred to crushed ice. The precipitated product is washed with cold water to remove any presence of acid and dried under high vacuum. (b) Synthesis of aniline derivative

[0066] N-(ethyl)-anilino ethanol (1 mmol) is mixed with tertiary butyl bromoacetate (1 .1 mmol) in benzene. A 50% NaOH solution is added to the reaction along with tetrabutyl ammonium hydrogen sulfate (phase transfer agent). Stirring continues at room temperature for 3 hours. The organic layer is evaporated to dryness and the product is purified using silica gel chromatography using hexane:ethyl acetate (19:1 ).

(c) Synthesis of squaraine dye

[0067] An aniline derivative (1 mmol) and semisquaraine (1 .1 mmol) is mixed in anhydrous 2-propanol. To this mixture 1 mL of dehydrating agent tributylorthoformate is added. The reaction mixture is refluxed for 3 hours. After cooling, the solvents are evaporated to dryness. Silica gel

chromatography in dichloromethane: methanol (97:3) gives the pure product.

(d) Synthesis of squaraine rotaxane

[0068] Clear solutions of the diacid dichloride (4 mmol) and p- xylylenediamine (4 mmol) in 5 mL chloroform are simultaneously added dropwise using a mechanical syringe pump apparatus over five hours to a stirred solution of squaraine dye (1 mmol) and triethylamine (4 mmol) in 40 mL of CHCI3. After stirring overnight, the reaction mixture is filtered through a pad of celite to remove any polymeric material, and the resulting crude product chromatographed using a silica gel column and a mixture of methanol/chloroform (1/19) as eluent.

(e) Synthesis of squaraine rotaxane carboxylic acid

[0069] Trifluoroacetic acid (TFA; 1 mL) is added to a solution of squaraine rotaxane (0.1 mmol) in CH₂Cl2 (5 mL). The mixture is stirred at room temperature for 6 hours, and the solvent and excess TFA evaporated under reduced pressure. The residue is washed with distilled water, and extracted with excess CH₂CI₂. The organic layer is dried with MgSO _, and the solvent is removed to afford azide-carboxylic acid rotaxane as a blue solid.

(f) Synthesis of squaraine rotaxane with attached zwitterionic group

[0070] Azide squaraine rotaxane (0.1 mmol) is dissolved in a mixture of THF:t-butanol:water (10 mL each). Excess of alkyne reagent is added and a mixture of CuSO₄-5H₂O (75 mg in 2 mL H₂O) and sodium ascorbate (300 mg in 3 mL H₂O) are also added. The solution is stirred overnight and the product purified by reverse-phase chromatography. (g) Synthesis of zwitterionic squaraine rotaxane that is activated for bioconjugation

[0071] Zwitterionic squaraine rotaxane carboxylic acid (0.1 mmol) is dissolved in 2 ml_ dimethylformamide (DMF). O-(N-Succinimidyl)-1 , 1 ,3,3- tetramethyluronium tetrafluoroborate (TSTU) (1 .1 eq) and

diisopropylethylamine (1 .1 eq) are added into the mixture and stirred overnight. Solvent is evaporated off and the crude product is washed with ether. The product is then dissolved in DMF and reprecipitated with ether, then dried under vacuum.

Synthesis of squaraine rotaxanes with the following general structure (or a pharmaceutically acceptable salt thereof):

[0072] According to embodiments, X = OH, alkoxy, aryloxy, NH-alkyl, NH-aryl, N-succinimide, NH-alkyl-maleimide, NH-polyethylene glycol-biotin, polyethylene glycol, methylene-sulfonate, methylene-dimethylammonium- alkyl-sulfonate, methylene-phosphonate, or methylene-dimethylammonium- alkyl-phosphonate.

[0073] In one specific, non-limiting example, the synthesis of a typical example (below) from this series is as follows:

(a) Synthesis of aniline substituted ferf-butyl ester

[0074] N-(diethanol) aniline (1 mmol) is mixed with tertiary butyl bromoacetate (1 .1 mmol) in benzene. A 50% NaOH solution is made and added to the reaction along with tetrabutyl ammonium hydrogen sulfate (phase transfer agent). Stirring continued at room temperature for 3 hours The organic layer is evaporated to dryness and the product purified using silica gel chromatography using hexane:ethyl acetate (9:1 ).

(b) Synthesis of tosylate

[0075] To a cooled solution of (1 mmol) in anhydrous pyridine (8 mmol) tosyl chloride (1 .1 mmol) is added in small amounts. The solution is allowed to stir for 4 hours. Reaction mixture is quenched with 30% HCI (100 mL) and extracted with dichloromethane. The organic layer is evaporated to dryness. (c) Synthesis of azide

[0076] Tosylate is dissolved in DMF and treated with an excess of NaN₃. This is refluxed for 16 hours. The reaction mixture was filtered and the solution was evaporated to dryness. This is purified using column chromatography using hexane: ethyl acetate (49:1 ).

(d) Synthesis of squaraine dye

[0077] Aniline derivatve (1 mmol) and semisquaraine (1 .1 mmol) are mixed in anhydrous 2-propanol. To this mixture 1 mL of dehydrating agent tributylorthoformate is added. The reaction mixture is refluxed for 3 hours. After cooling, the solvents are evaporated to dryness. Silica gel

chromatography in dichloromethane: methanol (19:1 ) gives the pure product.

(e) Synthesis of squaraine rotaxane

[0078] Clear solutions of the diacid dichloride (4 mmol) and p- xylylenediamine (4 mmol) in 5 mL chloroform are simultaneously added dropwise using a mechanical syringe pump apparatus over five hours to a stirred solution of squaraine dye (1 mmol) and triethylamine (4 mmol) in 40 mL of CHCI3. After stirring overnight, the reaction mixture is filtered through a pad of celite to remove any polymeric material, and the resulting crude product chromatographed using a silica gel column and a mixture of methanol/chloroform (1/19) as eluent.

(f) Synthesis of squaraine rotaxane carboxylic acid

[0079] Trifluoroacetic acid (TFA; 1 mL) is added to a solution of rotaxane (0.1 mmol) in CH₂Cl₂ (5 mL). The mixture is stirred at room temperature for 6 hours, and the solvent and excess TFA evaporated under reduced pressure. The residue is washed with distilled water, and extracted with excess CH₂CI₂. The organic layer is dried with MgSO₄ and the solvent removed to afford carboxylic acid rotaxane as a blue solid.

(g) Synthesis of squaraine rotaxane with two attached zwitterionic groups

[0080] Squaraine rotaxane (0.1 mmol) is dissolved in a mixture of THF:t-butanol:water (10 mL each). Excess of alkyne reagent is added and a mixture of CuSO₄-5H₂O (75 mg in 2 mL H₂O) and sodium ascorbate (300 mg in 3 mL H₂O) is also added. The solution is stirred overnight. Purification in reverse phase column gives the pure product. (h) Synthesis of zwitterionic squaraine rotaxane that is activated for bioconjugation

[0081] Zwitterionic squaraine rotaxane carboxylic acid (0.1 mmol) is dissolved in 2 ml_ DMF. TSTU (1 .1 eq) and diisopropylethylamine (1 .1 eq) are added into the mixture and stirred overnight. Solvent is evaporated off and the crude product is washed with ether. The product is then dissolved in DMF and reprecipitated with ether, and dried under vacuum.

3. Synthesis of squaraine rotaxanes with the following general structure (or a pharmaceutically acceptable salt thereof):

[0082] According to embodiments, X = OH, alkoxy, aryloxy, NH-alkyl, NH-aryl, N-succinimide, NH-alkyl-maleinnide, NH-polyethylene glycol-biotin, polyethylene glycol, methylene-sulfonate, methylene-dimethylammonium- alkyl-sulfonate, methylene-phosphonate, or methylene-dimethylammonium- alkyl-phosphonate.

[0083] In one specific, non-limiting example, the synthesis of a typical example (below) from this series is as follows:

(a) Synthesis of 4-azidopyridine-2,6- diacid dichloride

[0084] The known compound 4-chloropyridine-2,6- diacid dichloride is treated with tert-butanol to make the corresponding 4-chloropyridine-2,6- bis(tert-butyl ester) which is then treated with sodium azide to give 4- azidopyridyl-2,6-bis(tert-butyl ester) which is hydrolyzed with acid and subsequently treated with thionyl chloride to give the known 4-azidopyridyl- 2,6- diacid dichloride,

(b) Synthesis of squaraine rotaxane

[0085] Clear solutions of the 4-azidopyridyl-2,6-diacid dichloride (4 mmol) and p-xylylenediamine (4 mmol) in 5 ml_ chloroform are

simultaneously added dropwise using a mechanical syringe pump apparatus over five hours to a stirred solution of squaraine dye (1 mmol) and triethylamine (4 mmol) in 40 ml_ of CHCI3. After stirring overnight, the reaction mixture is filtered through a pad of celite to remove any polymeric material, and the resulting crude product was chromatographed using a silica gel column and a mixture of methanol/chloroform (1/19) as eluent.

(c) Synthesis of squaraine rotaxane carboxylic acid

[0086] Trifluoroacetic acid (1 ml_) is added to a solution of azide squaraine rotaxane (0.1 mmol) in CH₂Cl2 (5 ml_). The mixture is stirred at room temperature for 6 hours, and the solvent and excess TFA are evaporated under reduced pressure. The residue is washed with distilled water, and extracted with excess CH2CI2. The organic layer is dried with MgSO₄ and the solvent removed to afford carboxylic acid rotaxane as a blue solid.

(d) Synthesis of squaraine rotaxane with three attached zwitterionic groups

[0087] Azide squaraine rotaxane (0.1 mmol) is dissolved in a mixture of THF:t-butanol:water (10 mL each). Excess of alkyne reagent is added and a mixture of CuSO₄-5H₂O (75 mg in 1 mL H₂O) and sodium ascorbate (300 mg in 3 mL H₂O) is also added. The solution is stirred overnight. Purification in reverse phase column gives the pure product.

(e) Synthesis of zwitterionic squaraine rotaxane that is activated for bioconjugation

[0088] Zwitterionic squaraine rotaxane carboxylic acid (0.1 mmol) is dissolved 2 mL DMF. TSTU (1 .1 eq) and diisopropylethylannine (1 .1 eq) are added into the mixture and stirred overnight. Solvent is evaporated and the crude product is washed with ether. The product is then dissolved in DMF and reprecipitated with ether, then dried under vacuum. 4. Synthesis of squaraine rotaxanes with the following general structure (or a pharmaceutically acceptable salt thereof):

where T¹, T², T³, T⁴, and T⁵ are each independently H or 1 ,3-triazole rings; and W¹, W², W³, and W⁴ are each independently H or OH.

[0089] In one specific, non-limiting example, the synthesis of a typical intermediate in this series is as follows:

[0090] Clear solutions of the pyridine-2,6-dicarbonyl dichloride (1 .92 mmol) and 1 ,4-xylylenediamine (1 .92 mmol) in anhydrous chloroform (30 mL) are added dropwise over 5 hours, using a mechanical syringe pump, to a stirred solution containing the squaraine dye (0.38 mmol) and triethylamine (4.42 mmol) in anhydrous chloroform (150 mL). After stirring overnight, the reaction is filtered through a pad of Celite to remove any polymeric material. The solvent is removed by rotary evaporation, and the crude product purified by column chromatography using a column of silica gel with MeOH/CHCl3 (1 :19).

[0091] In one specific, non-limiting example, the synthesis of a typical example in this series is as follows: (a) Rotaxane synthesis

[0092] Clear solutions of the pyridine-2,6-dicarbonyl dichloride (2 mmol) and 1 ,4-xylylenediamine (2 mmol) in anhydrous chloroform (30 ml_) are added dropwise over 5 hours, using a mechanical syringe pump, to a stirred solution containing the squaraine dye (0.4 mmol) and triethylamine (4 mmol) in anhydrous chloroform (150 ml_). After stirring overnight, the reaction is filtered through a pad of Celite to remove any polymeric material. The solvent is removed by rotary evaporation, and the crude product purified by column chromatography using a column of silica gel.

(b) Attachment of zwitterionic group

[0093] Azide squaraine rotaxane (0.1 mmol) is dissolved in a mixture of THF:t-butanol:water (10 ml_ each). Excess of alkyne reagent is added and a mixture of CuSO -5H₂O (75 mg in 1 ml_ H₂O) and sodium ascorbate (300 mg in 3 ml_ H₂O) is also added. The solution is stirred overnight.

Purification in reverse phase column gives the pure product. [0094] In one specific, non-limiting example, the synthesis of a typical intermediate in this series is as follows:

[0095] Clear solutions of the pyridine-2,6-dicarbonyl dichloride (2 mmol) and 1 ,4-xylylenediamine (2 mmol) in anhydrous chloroform (30 ml_) are added dropwise over 5 hours, using a mechanical syringe pump, to a stirred solution containing the squaraine dye (0.4 mmol) and tnethylamine (4 mmol) in anhydrous chloroform (150 ml_). After stirring overnight, the reaction is filtered through a pad of Celite to remove any polymeric material. The solvent is removed by rotary evaporation, and the crude product purified by column chromatography using a column of silica gel.

[0096] In one specific, non-limiting example, the synthesis of a typical intermediate in this series is as follows:

[0097] Clear solutions of the pyridine-2,6-dicarbonyl dichloride (2 mmol) and 1 ,4-xylylenediamine (2 mmol) in anhydrous chloroform (30 ml_) are added dropwise over 5 hours, using a mechanical syringe pump, to a stirred solution containing the squaraine dye (0.4 mmol) and triethylamine (4 mmol) in anhydrous chloroform (150 ml_). After stirring overnight, the reaction is filtered through a pad of Celite to remove any polymeric material. The solvent is removed by rotary evaporation, and the crude product purified by column chromatography using a column of silica gel.

5. Synthesis of squaraine rotaxanes with the following general structure (or a pharmaceutically acceptable salt thereof):

where T¹, T², T³, T⁴, T⁵ are each independently H or a 1 ,3-triazole rings, and W¹ , W², W³, and W⁴ are each independently H or OH

[0098] In one specific, non-limiting example, the synthesis of a typical intermediate in this series is as follows:

[0099] The pyridyl anthracene macrocycle (10 mmol) is mixed with the squaraine dye (10 mmol) in chloroform (19 mL) and the solution heated to 160°C using a microwave oven. After 5 minutes the desired squaraien rotaxane is obtained after removal of the solvent and chromatography. [00100] In one specific, non-limiting example, the synthesis of a typical intermediate in this series is as follows:

[00101] The pyridyl anthracene macrocycle (10 mmol) is mixed with the squaraine dye (10 mmol) in chloroform (19 mL) and the solution heated to 160°C using a microwave oven. After 5 minutes the desired squaraien rotaxane is obtained after removal of the solvent and chromatography.

[00102] In one specific, non-limiting example, the synthesis of a typical intermediate in this series is as follows:

(a) Rotaxane synthesis

[00103] The pyridyl anthracene macrocycle (10 mmol) is mixed with the squaraine dye (10 mmol) in chloroform (19 mL) and the solution heated to 160°C using a microwave oven. After 5 minutes the desired squaraine rotaxane is obtained in quantitative yield.

(b) Attachment of zwitterionic groups

[00104] Azide squaraine rotaxane (0.1 mmol) is dissolved in a mixture of THF:t-butanol:water (10 ml_ each). Excess of alkyne reagent is added and a mixture of CuSO -5H₂O (75 mg in 1 ml_ H₂O) and sodium ascorbate (300 mg in 3 ml_ H₂O) is also added. The solution is stirred overnight. Purification in a reverse phase column gives the pure product.

Cell Labeling

[00105] Fluorescent dyes are often used to covalently label cells and allow studies of cell motility, proliferation, and migration.

[00106] Cells are washed and resuspended in 0.1 % (bovine serum albumin) BSA/PBS to a concentration of 10⁷ cells/mL. Labeling with squaraine rotaxane N-hydroxysuccinimde ester is performed by adding an aliquot of the squaraine rotaxane N-hydroxysuccinimde ester (50 mM stock in DSMO) to a give a final concentration of 0.5 μΜ, and incubating the cells for 30 minutes at 37°C. The cells are washed extensively and resuspended in the appropriate buffer for microscopic studies. The cells are imaged by confocal microscopy using a Cy-5 filter set. Protein Labeling

[00107] Fluorescent dyes are often used to covalently label proteins, especially antibodies, and allow detection assays for various applications in biotechnology, medicine, public health, and national security.

[00108] Anti-rabbit IgG antibodies (2 mg/nnL) in sodium bicarbonate buffer (0.1 M, pH 8.3) are labeled by adding an aliquot of squaraine rotaxane N-hydroxysuccinimde ester (50 mM stock in DSMO) to a give a final concentration of 5 mg/nnL, and incubating for one hour at 37°C in the dark. Unconjugated dye is separated from the labeled protein by size-exclusion chromatography using 30,000 MW resin and sodium phosphate buffer (50 mM, pH 7.3) as eluent. The dye/protein ratio is determined spectrometrically from the molar absorptivity of 180,000 cm^"1 M^"1 for the dye at 640 nm, and 203,000 cm^"1 M^"1 for the antibody at 280 nm (this includes the contribution from attached dye).

Oligonucleotide Labeling

[00109] Fluorescent dyes are often used to covalently label

oligonucleotides, especially DNA, and allow detection assays for various applications in biotechnology, medicine, public health, and national security.

[00110] Oligonucleotide (2 img/mL) is desalted with a NAP 5 column and placed in sodium bicarbonate buffer (0.1 M, pH 8.3). Labeling is achieved by adding an aliquot of squaraine rotaxane N-hydroxysuccinimde ester (50 mM stock in DSMO) to a give a final concentration of 5 img/mL, and incubating for one hour at 37°C in the dark. Unconjugated dye was separated from the oligonucleotide by size-exclusion chromatography using a Sephadex 25 column followed by ethanol precipitation and the labeled and unlabeled oligonucleotides are separated by gel electrophoresis. The bands containing the labeled oligonucleotide are identified and excised. The oligonucleotide is extracted using 10 mM tris-HCI and then purified by extraction with phenol/chloroform/isoamyl alcohol, ethanol precipitation, and desalting with a NAP 5 column. [00111] Although certain embodiments have been illustrated and described herein, it will be appreciated by those of ordinary skill in the art that a wide variety of alternate and/or equivalent embodiments or implementations calculated to achieve the same purposes may be substituted for the embodiments shown and described without departing from the scope. Those with skill in the art will readily appreciate that embodiments may be implemented in a very wide variety of ways. This application is intended to cover any adaptations or variations of the embodiments discussed herein. Therefore, it is manifestly intended that embodiments be limited only by the claims and the equivalents thereof.

Claims

What is claimed is:

1 . A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

R¹ , R², and R³ are each independently alkyi, phenyl, polyethylene glycol, alkyl-phosphonate, alkyl-sulfonate, methylene-triazole-alkyl-sulfonate, methylene-triazole-alkyl-phosphonate, methylene-triazole-methylene- dimethylammonium-alkyl-sulfonate, or methylene-dimethylammonium-alkyl- phosphonate;

X = alkyi, phenyl, alkyl-carboxylic acid, alkyi ester, alkyi

hydroxysuccinimde ester, alkyi maleimide, alkyi isothiocyanate, alkyi azide, alky alkyne, alkyi haloacetamido, aryl ester, aryl hydroxysuccinimde ester, aryl maleimide, aryl isothiocyanate, aryl azide, aryl alkyne, or aryl

haloacetamido;

Y¹ and Y² are each independently H, alkoxy-triazole- methylene- sulfonate, alkoxy-triazole-methylene-dimethylammonium-alkyl-sulfonate, alkoxy-triazole-methylene-phosphonate, alkoxy-triazole-methylene- dimethylammonium-alkyl- phosphonate, triazole-methylene-sulfonate, triazole-methylene-phosphonate; triazole-methylene-dimethylammonium- alkyl-sulfonate, triazole-methylene- methylene-dimethylammonium-alkyl- phosphonate, alkyi, phenyl, alkyl-carboxylic acid, alkyi ester, alkyi

hydroxysuccinimde ester, alkyi maleimide, alkyi isothiocyanate, alkyi azide, alky alkyne, alkyl haloacetamido, aryl ester, aryl hydroxysuccinimde ester, aryl maleimide, aryl isothiocyanate, aryl azide, aryl alkyne, or aryl

haloacetam;

Z¹ and Z² are each independently CH or N; and

W¹ , W², W³, and W⁴ are each independently H or OH.

2. The compound of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof, wherein:

X = OH, alkoxy, aryloxy, oxy-succinimide, NH-alkyl-maleimide, or NH- polyethylene glycol-biotin;

T¹, T², T³, T⁴, and T⁵ are each independently H or a 1 ,3-triazole ring that is substituted with a group R, wherein R = polyethylene glycol, methylene-dimethylammonium-alkyl-sulfonate, or methylene- dimethylammonium-alkyl-phosphonate; and

Z = CH or N.

3. The compound of claim 2, wherein the compound has the formula:

4. The compound of claim 2, wherein the compound has the formula:

The compound of claim 4, wherein the compound has the formula:

The compound of claim 4, wherein the compound has the formula:

The compound of claim 1 , wherein the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein

X = OH, alkoxy, aryloxy, oxy-succinimide, NH-alkyl-maleimide, NH- polyethylene glycol-biotin;

T¹, T², T³, T⁴, and T⁵ are each independently H or a 1 ,3-triazole ring that is substituted with a group R, wherein R = polyethylene glycol, alkyl- sulfonate, alkyl-phosphonate, methylene-dimethylammonium-alkyl-sulfonate, or methylene-dimethylammonium-alkyl-phosphonate; and

Z = CH or N.

8. The compound of claim 7, wherein the compound has the formula:

9. The compound of claim 7, wherein the compound has the formula:

10. The compound of claim 7, wherein the compound has the formula:

1 1 . The compound of claim 7, wherein the compound has the formula:

12. The compound of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof, wherein;

Z = CH or N.

13. The compound of claim 12, wherein the compound has the formula:

The compound of claim 12, wherein the compound has the formula

The compound of claim 12, wherein the compound has the formula

The compound of claim 12, wherein the compound has the formula

The compound of claim 1 , wherein the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein

Z = CH or N.

18. The compound of claim 17, wherein the compound has the formula:

he compound of claim 17, wherein the compound has the formula

The compound of claim 17, wherein the compound has the formula

The compound of claim 20, wherein the compound has the formula

The compound of claim 1 , wherein the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein:

Z = CH or N.

23. The compound of claim 22, wherein the compound has the formula:

The compound of claim 22, wherein the compound has the formula

The compound of claim 22, wherein the compound has the formula

The compound of claim 22, wherein the compound has the formula

The compound of claim 1 , wherein the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein:

Z = CH or N.

The compound of claim 27, wherein the compound has the formula

The compound of claim 27, wherein the compound has the formula

The compound of claim 27, wherein the compound has the formula

The compound of claim 27, wherein the compound has the formula

A compound having the formula

or a pharmaceutically acceptable salt thereof, wherein:

R¹ , R², and R³ are each independently alkyi, phenyl, polyethylene glycol, alkyl-phosphonate, alkyl-sulfonate, methylene-triazole- alkyl-sulfonate, methylene-triazole-alkyl-phosphonate, methylene-triazole- methylene-dimethylammonium-alkyl-sulfonate, or methylene- dimethylammonium-alkyl-phosphonate;

X = alkyi, phenyl, alkyl-carboxylic acid, alkyi ester, alkyi

hydroxysuccinimde ester, alkyi maleimide, alkyi isothiocyanate, alkyi azide, alky alkyne, alkyi haloacetamido, aryl ester, aryl hydroxysuccinimde ester, aryl maleimide, aryl isothiocyanate, aryl azide, aryl alkyne, or aryl haloacetamido;

Y¹ and Y² are each independently H, alkoxy-triazole- methylene- sulfonate, alkoxy-triazole-methylene-dimethylammonium-alkyl-sulfonate, alkoxy-triazole-methylene-phosphonate, alkoxy-triazole-methylene- dimethylammonium-alkyl- phosphonate, triazole-methylene-sulfonate, triazole-methylene-phosphonate; triazole-methylene-dimethylammonium- alkyl-sulfonate, triazole-methylene- methylene-dimethylammonium-alkyl- phosphonate, alkyi, phenyl, alkyl-carboxylic acid, alkyi ester, alkyi hydroxysuccinimde ester, alkyi maleimide, alkyi isothiocyanate, alkyi azide, alkyi alkyne, alkyi haloacetamido, aryl ester, aryl hydroxysuccinimde ester, aryl maleimide, aryl isothiocyanate, aryl azide, aryl alkyne, or aryl

haloacetamido; and

W¹ , W², W³, and W⁴ are each independently H or OH.

33. The compound of claim 32, wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof, wherein:

X = OH, alkoxy, aryloxy, oxy-succinimide, NH-alkyl-maleimide, or NH- polyethylene glycol-biotin; and

T¹, T², T³, T⁴, and T⁵ are each independently H or a 1 ,3-triazole ring that is substituted with a group R, wherein R = polyethylene glycol, methylene-dimethylammonium-alkyl-sulfonate, or methylene- dimethylammonium-alkyl-phosphonate.

The compound of claim 33, wherein the compound has the formula

The compound of claim 33, wherein the compound has the formula

The compound of claim 32, wherein the compound has the formula

37. The compound of claim 33, wherein the compound has the formula:

38. The compound of claim 32, wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof, wherein:

T¹, T², T³, T⁴, and T⁵ are each independently H or a 1 ,3-triazole ring that is substituted with a group R, wherein R = polyethylene glycol, alkyl- sulfonate, alkyl-phosphonate, methylene-dimethylammonium-alkyl-sulfonate, or methylene-dimethylammonium-alkyl-phosphonate. The compound of claim 38, wherein the compound has the formula

The compound of claim 39, wherein the compound has the formula

The compound of claim 38, wherein the compound has the formula

The compound of claim 38, wherein the compound has the formula

The compound of claim 32, wherein the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein:

T¹, T², T³, T⁴, and T⁵ are each independently H or a 1 ,3-triazole ring that is substituted with a group R, wherein R = polyethylene glycol, alkyl- sulfonate, alkyl-phosphonate, methylene-dimethylammonium-alkyl-sulfonate, or methylene-dimethylammonium-alkyl-phosphonate.

44. The compound of claim 43, wherein the compound has the formula

45. The formula

The compound of claim 43, wherein the compound has the formula

The com ound of claim 46, wherein the com ound has the formula

The compound of claim 32, wherein the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein:

T¹, T², T³, T⁴, and T⁵ are each independently H or a 1 ,3-triazole ring that is substituted with a group R, wherein R = polyethylene glycol, alkyl- sulfonate, alkyl-phosphonate, methylene-dimethylammonium-alkyl-sulfonate, or methylene-dimethylammonium-alkyl-phosphonate. The compound of claim 48, wherein the compound has the formula

The compound of claim 48, wherein the compound has the formula

The compound of claim 48, wherein the compound has the formula

The compound of claim 48, wherein the compound has the formula

The compound of claim 32, wherein the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein:

T¹, T², T³, T⁴, and T⁵ are each independently H or a 1 ,3-triazole ring that is substituted with a group R, wherein R = polyethylene glycol, alkyl- sulfonate, or alkyl-phosphonate. The compound of claim 53, wherein the compound has the formula

The compound of claim 54, wherein the compound has the formula

The compound of claim 53, wherein the compound has the formula

The compound of claim 56, wherein the compound has the formula

The compound of claim 32, wherein the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein:

T¹, T², T³, T⁴, and T⁵ are each independently H or a 1 ,3-triazole ring that is substituted with a group R, wherein R = polyethylene glycol, alkyl- sulfonate, or alkyl-phosphonate.

59. The compound of claim 58, wherein the compound has the formula:

60. The compound of claim 58, wherein the compound has the formula:

61 . The compound of claim 58, wherein the compound has the formula:

The compound of claim 58, wherein the compound has the formula

A compound having the formula

or a pharmaceutically acceptable salt thereof, wherein:

R¹ , R², and R³ are each independently alkyi, phenyl, polyethylene glycol, alkyl-phosphonate, alkyl-sulfonate, methylene-triazole- alkyl-sulfonate, or methylene-triazole-alkyl-phosphonate, methylene-triazole- methylene-dimethylammonium-alkyl-sulfonate, or methylene- dimethylammonium-alkyl-phosphonate;

X = alkyi, phenyl, alkyl-carboxylic acid, alkyi ester, alkyi

haloacetamido;

Y¹ and Y² are each independently H, alkoxy-triazole- methylene- sulfonate, alkoxy-triazole-methylene-dimethylammonium-alkyl-sulfonate, alkoxy-triazole-methylene-phosphonate, alkoxy-triazole-methylene- dimethylammonium-alkyl- phosphonate, triazole-methylene-sulfonate, triazole-methylene-phosphonate; triazole-methylene-dimethylammonium- alkyl-sulfonate, triazole-methylene- methylene-dimethylammonium-alkyl- phosphonate, alkyi, phenyl, alkyl-carboxylic acid, alkyi ester, alkyi hydroxysuccinimde ester, alkyi maleimide, alkyi isothiocyanate, alkyi azide, alky alkyne, alkyi haloacetamido, aryl ester, aryl hydroxysuccinimde ester, aryl maleimide, aryl isothiocyanate, aryl azide, aryl alkyne, or aryl

haloacetamido; and

W¹ , W², W³, and W⁴ are each independently H or OH.

64. A method of synthesizing a water-soluble squarane rotaxane, comprising: fabricating a central squaraine thread component; encapsulating the thread component inside a macrocycle to make a squaraine rotaxane; and attaching a water-solubilizing group to the squaraine rotaxane by forming a triazole linkage.

65. The method of claim 64, further comprising the step of covalently modifying the rotaxane.

66. The method of claim 64, wherein the triazole linkage is formed using a copper-catalyzed azide alkyne cycloaddition reaction.